Actively Recruiting

Phase Not Applicable
Age: 20Years - 37Years
All Genders
NCT06561451

Live Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia

Led by ShangHai Ji Ai Genetics & IVF Institute · Updated on 2026-02-02

208

Participants Needed

1

Research Sites

173 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to compare the live birth rate between intracytoplasmic sperm injection (ICSI) and artificial oocyte activation (AOA) vs intracytoplasmic sperm injection alone in patients with teratospermia. The hypothesis is the live birth rate following ICSI and AOA is significantly higher than that by ICSI alone in patients with teratospermia. This is a randomized controlled trial. Participants will be randomly assigned into one of the two groups: ICSI+AOA group: a single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions. ICSI alone group: a single sperm will be injected within 4 hours after the follicular aspiration.

CONDITIONS

Official Title

Live Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia

Who Can Participate

Age: 20Years - 37Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Women aged 20 to 37 years at the time of ovarian stimulation for ICSI
  • At least three matured oocytes collected
  • Severe teratozoospermia defined as abnormal sperm morphology of 99-100%, including globozoospermia and tapered-head
Not Eligible

You will not qualify if you...

  • Presence of untreated hydrosalpinx
  • Undergoing preimplantation genetic testing
  • History of recurrent pregnancy loss defined as two or more spontaneous pregnancy losses
  • Known uterine abnormalities such as congenital malformations, untreated uterine septum, adenomyosis, submucous myoma, endometrial polyps, or intrauterine adhesions
  • Abnormal parental karyotyping or medical conditions that contraindicate assisted reproductive technology or pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

ShangHai JIAI Genetics &I VF Institute

Shanghai, China

Actively Recruiting

Loading map...

Research Team

H

HE LI, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Live Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia | DecenTrialz